Welcome to our dedicated page for Tillys SEC filings (Ticker: TLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tillys may look like a laid-back surf shop, but its SEC disclosures tell a far deeper story. From seasonal inventory swings to mall-lease commitments, each filing reveals how the youth-lifestyle retailer manages risk while chasing trends. If you have ever searched for “Tillys insider trading Form 4 transactions” or wondered which quarter drives back-to-school sales, you’re in the right place.
Stock Titan’s AI reads every word of the Tillys annual report 10-K simplified and the latest Tillys quarterly earnings report 10-Q filing, then translates accounting jargon into plain English. Need to track “Tillys Form 4 insider transactions real-time” or decode an unexpected Tillys 8-K material events explained? Our platform flags those updates the moment EDGAR releases them and delivers concise takeaways so you can act quickly.
Here’s what you’ll uncover:
- Store counts, sales per square foot, and lease obligations pulled directly from the 10-K
- Comp-store and e-commerce trends from each 10-Q—ideal for fast Tillys earnings report filing analysis
- Real-time alerts on Tillys executive stock transactions Form 4 to spot insider sentiment shifts
- “Tillys proxy statement executive compensation” details that link bonuses to same-store sales targets
Whether you’re understanding Tillys SEC documents with AI for a quick trade or building a long-term thesis, our expert commentary, AI-powered summaries, and full-text search remove the guesswork. Every material disclosure—10-K, 10-Q, 8-K, Form 4, S-8, or DEF 14A—is here, updated in real time and explained simply.
Kineta, LLC (successor by merger to Kineta, Inc.) has filed nine Post-Effective Amendment No. 1s to previously effective Form S-8 registration statements to deregister all unsold shares that had been reserved for multiple legacy equity incentive and employee stock purchase plans. The administrative action follows the 30 June 2025 closing of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. and was converted into Kineta, LLC. Because the stand-alone plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta are now terminated, the related offerings are deemed concluded, triggering removal of the remaining registered securities. The amendments span Registration Statement Nos. 333-210521, 333-218544, 333-223664, 333-230155, 333-237181, 333-252691, 333-252692, 333-256853 and 333-268969, which collectively covered millions of potential shares across the 2008, 2016, 2018, 2020 and 2022 equity plans and various inducement grants. No new securities are being registered, no financial statements are provided, and the filing does not alter the merger consideration already distributed to former Kineta shareholders. The primary effect is the elimination of potential future dilution from the unissued shares and formal alignment of the capital structure with the post-merger entity.
FAQ
What is the current stock price of Tillys (TLYS)?
What is the market cap of Tillys (TLYS)?
What is the core business of Tillys Inc?
How does Tillys generate revenue?
Which market segments does Tillys serve?
What distinguishes Tillys from its competitors?
How does Tillys stay current with industry trends?
What role does the online store play for Tillys?
How does Tillys ensure a unique customer experience?
How is Tillys’ product assortment maintained?
